Mark D. Booth
2010
In 2010, Mark D. Booth earned a total compensation of $1.1M as Chief Commercial Officer at Orexigen Therapeutics, a 66% decrease compared to previous year.
Compensation breakdown
| Bonus | $262,500 |
|---|---|
| Option Awards | $488,271 |
| Salary | $350,000 |
| Other | $7,626 |
| Total | $1,108,397 |
Booth received $488.3K in option awards, accounting for 44% of the total pay in 2010.
Booth also received $262.5K in bonus, $350K in salary and $7.6K in other compensation.
Rankings
In 2010, Mark D. Booth's compensation ranked 4,918th out of 10,439 executives tracked by ExecPay. In other words, Booth earned more than 52.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,918 out of 10,439 | 53rd |
Division Manufacturing | 1,761 out of 3,838 | 54th |
Major group Chemicals And Allied Products | 360 out of 921 | 61st |
Industry group Drugs | 210 out of 680 | 69th |
Industry Pharmaceutical Preparations | 163 out of 481 | 66th |
Source: SEC filing on April 23, 2013.
Booth's colleagues
We found five more compensation records of executives who worked with Mark D. Booth at Orexigen Therapeutics in 2010.
2010
Michael Narachi
Orexigen Therapeutics
Chief Executive Officer
2010
Heather Turner
Orexigen Therapeutics
General Counsel
2010
Graham Cooper
Orexigen Therapeutics
Chief Financial Officer
2010
Preston Klassen
Orexigen Therapeutics
Head of Global Contrave Program and Senior Vice President, Product Development
2010
Joseph Hagan
Orexigen Therapeutics